Comparable graft and patient survival in lean and obese liver transplant recipients

Silvia E. Perez-Protto, Cristiano Quintini, Luke F. Reynolds, Jing You, Jacek B. Cywinski, Daniel I. Sessler, Charles Miller – 7 June 2013 – Obesity is among the great health problems facing Americans today. More than 32% of the US population is considered obese on the basis of a body mass index (BMI) exceeding 30 kg/m2. Obesity increases the risk for numerous perioperative complications, but how obesity affects the outcome of liver transplantation remains unclear.

Surgical site infections in liver transplant recipients in the model for end‐stage liver disease era: An analysis of the epidemiology, risk factors, and outcomes

Maristela Pinheiro Freire, Isabel C. V. Soares Oshiro, Patricia Rodrigues Bonazzi, Thais Guimarães, Estela Regina Ramos Figueira, Telésforo Bacchella, Silvia Figueiredo Costa, Luiz Augusto Carneiro D'Albuquerque, Edson Abdala – 7 June 2013 – In recipients of liver transplantation (LT), surgical site infection (SSIs) are among the most common types of infection occurring in the first 60 days after LT. In 2007, the Model for End‐Stage Liver Disease (MELD) scoring system was adopted as the basis for prioritizing organ allocation.

Vasoactive intestinal peptide attenuates liver ischemia/reperfusion injury in mice via the cyclic adenosine monophosphate–protein kinase a pathway

Haofeng Ji, Yu Zhang, Yuanxing Liu, Xiu‐Da Shen, Feng Gao, Terry T. Nguyen, Ronald W. Busuttil, James A. Waschek, Jerzy W. Kupiec‐Weglinski – 7 June 2013 – Hepatic ischemia/reperfusion injury (IRI), an exogenous, antigen‐independent, local inflammation response, occurs in multiple clinical settings, including liver transplantation, hepatic resection, trauma, and shock. The nervous system maintains extensive crosstalk with the immune system through neuropeptide and peptide hormone networks.

Liver iron modulates hepcidin expression during chronically elevated erythropoiesis in mice

Víctor Díaz, Elena Gammella, Stefania Recalcati, Paolo Santambrogio, Arianne Monge Naldi, Johannes Vogel, Max Gassmann, Gaetano Cairo – 6 June 2013 – The liver‐derived peptide hepcidin controls the balance between iron demand and iron supply. By inhibiting the iron export activity of ferroportin, hepcidin modulates iron absorption and delivery from the body's stores. The regulation of hepcidin, however, is not completely understood and includes a variety of different signals.

Sleep‐wake abnormalities in patients with cirrhosis

Sara Montagnese, Cristiano De Pittà, Michele De Rui, Michela Corrias, Matteo Turco, Carlo Merkel, Piero Amodio, Rodolfo Costa, Debra J. Skene, Angelo Gatta – 6 June 2013 – A considerable proportion of patients with cirrhosis exhibit insomnia, delayed sleep habits, and excessive daytime sleepiness. These have been variously attributed to hepatic encephalopathy and impaired hepatic melatonin metabolism, but the understanding of their pathophysiology remains limited and their treatment problematic. Sleep is regulated by the interaction of a homeostatic and a circadian process.

Protein kinase a‐dependent pSer675‐β‐catenin, a novel signaling defect in a mouse model of congenital hepatic fibrosis

Carlo Spirli, Luigi Locatelli, Carola M. Morell, Romina Fiorotto, Stuart D. Morton, Massimiliano Cadamuro, Luca Fabris, Mario Strazzabosco – 6 June 2013 – Genetically determined loss of fibrocystin function causes congenital hepatic fibrosis (CHF), Caroli disease (CD), and autosomal recessive polycystic kidney disease (ARPKD). Cystic dysplasia of the intrahepatic bile ducts and progressive portal fibrosis characterize liver pathology in CHF/CD.

Subscribe to